State Street Health Care ETF (XLV) has outperformed Invesco Pharma ETF (PJP) on both cost and size, according to a recent analysis by The Motley Fool. The healthcare sector ETF offers a lower expense ratio and a larger asset base than its pharma-focused competitor, making it a more cost-effective and liquid option for investors seeking exposure to healthcare stocks.

Key Takeaways

  • State Street Health Care ETF (XLV) has an expense ratio of 0.10%, significantly lower than Invesco Pharma ETF (PJP) at 0.55%.
  • XLV has over $30 billion in assets under management, while PJP has less than $500 million.
  • XLV tracks a broad healthcare index, while PJP focuses exclusively on pharmaceutical companies.
  • Lower costs and higher liquidity make XLV a more efficient choice for long-term investors.

Overview of the Two ETFs

State Street Health Care ETF (XLV) is one of the largest healthcare sector ETFs, tracking the Health Care Select Sector Index. It includes a diversified mix of healthcare giants such as UnitedHealth Group, Johnson & Johnson, Pfizer, and Merck. Invesco Pharma ETF (PJP), on the other hand, focuses purely on pharmaceutical companies, following the Dynamic Pharmaceutical Intellidex Index. Both ETFs trade on major U.S. exchanges and aim to provide targeted exposure to the healthcare industry.

Cost Comparison: Expense Ratios

The expense ratio is a key factor for any ETF investor. XLV charges 0.10% per year, meaning a $10,000 investment costs just $10 annually. PJP is more expensive, with a fee of 0.55%, or $55 per year on the same amount. Over time, this difference compounds, making XLV far more cost effective for long-term holders. According to The Motley Fool report, the lower fee is a major advantage for XLV, especially for investors who plan to hold the ETF for years.

Size and Liquidity

XLV has more than $30 billion in assets under management, while PJP has less than $500 million. Larger funds typically offer better liquidity, which means tighter bid ask spreads and lower trading costs. The Motley Fool notes that XLV trades millions of shares daily, while PJP sees much lower volume. For investors who may need to buy or sell in size, XLV is clearly the more liquid option. A larger asset base also indicates broader investor confidence and a more stable structure.

Sector Exposure and Diversification

XLV holds about 65 stocks spanning healthcare equipment, managed care, biotechnology, pharmaceuticals, and life sciences. PJP concentrates on roughly 30 pharmaceutical companies, giving it a narrower focus. The Motley Fool report points out that PJP’s reliance on a single subsector means it may be more volatile and less diversified. For investors seeking broad healthcare exposure, XLV offers a more balanced approach. For those who want pure pharma plays, PJP remains an option, but at a higher cost and lower liquidity.

Performance and Yield Considerations

Historical performance varies, but XLV has generally tracked the broader healthcare sector closely, benefiting from its diverse holdings. PJP may outperform or underperform depending on the pharmaceutical cycle. Both ETFs pay dividends, with XLV yielding around 1.4% and PJP yielding about 1.0% as of the report’s data. However, past performance does not guarantee future results. The Motley Fool analysis suggests that given the cost and liquidity advantages, XLV is the more reliable choice for most investors.

Which ETF Should You Choose?

The Motley Fool concludes that State Street Health Care ETF is the better option for the majority of investors due to its lower expense ratio, vastly larger asset base, and wider diversification. Invesco Pharma ETF may appeal to those who specifically want to overweight pharmaceutical stocks and are willing to accept higher costs and lower liquidity. For a core healthcare holding, XLV offers a simple, low cost solution that has stood the test of time.

Frequently Asked Questions

Is State Street Health Care ETF a good investment for 2025?

The Motley Fool report does not provide specific 2025 predictions, but XLV’s low costs and broad diversification make it a solid core holding for healthcare exposure. Investors should consider their own risk tolerance and portfolio goals before investing.

What is the difference between XLV and PJP?

XLV tracks a broad healthcare index with stocks from multiple subsectors including managed care, biotech, and equipment. PJP focuses only on pharmaceutical companies. XLV also has a much lower expense ratio (0.10% vs. 0.55%) and far larger assets under management.

Which healthcare ETF is more cost effective?

State Street Health Care ETF is more cost effective than Invesco Pharma ETF, according to The Motley Fool. Its 0.10% expense ratio is one of the lowest among healthcare ETFs, while PJP’s 0.55% fee is relatively high for a sector fund.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.